Insulin Lispro
- Generic Name
- Insulin Lispro
- Brand Names
- Admelog, Humalog, Humalog Mix, Humalog kwikpen, Liprolog, Lyumjev, Insulin lispro Sanofi, Lyumjev (previously Liumjev)
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 133107-64-9
- Unique Ingredient Identifier
- GFX7QIS1II
- Background
Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is release...
- Indication
本品尤其适用于下列情况：
1.经常发生低血糖的1型糖尿病者，使用本品可减少低血糖的发生率；
2.生活不规律，外出活动较多的用胰岛素治疗的糖尿病患者，本品快速、短效的特点有助于及时调整胰岛素的用量。
- Associated Conditions
- Diabetes Mellitus, Diabetic Ketoacidosis, Gestational Diabetes Mellitus (GDM)
- Associated Therapies
- -
Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study)
- Conditions
- Interventions
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2021-12-06
- Target Recruit Count
- 300
- Registration Number
- NCT03328845
- Locations
- 🇪🇸
Regional University Hospital of Málaga, Málaga, Spain
A Study of LY900014 in Participants With Type 2 Diabetes Mellitus
- First Posted Date
- 2017-10-10
- Last Posted Date
- 2020-05-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 38
- Registration Number
- NCT03305822
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss, Nordrhein-Westfalen, Germany
A Comparative Study of LY900014 to Insulin Lispro (Humalog) in Healthy Participants
- First Posted Date
- 2017-09-18
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 42
- Registration Number
- NCT03286751
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss, Germany
Effects of Insulin on Hypotension and Sarcopenia
- First Posted Date
- 2017-08-14
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Kenneth Madden
- Registration Number
- NCT03248271
- Locations
- 🇨🇦
University of British Columbia - Gerontology Research Lab, Vancouver, British Columbia, Canada
Dynamics of Insulin Absorption in Subclinical Lipohypertrophy Using the Euglycemic Clamp Technique
- First Posted Date
- 2017-07-26
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Graydon Meneilly
- Target Recruit Count
- 10
- Registration Number
- NCT03229850
- Locations
- 🇨🇦
University of British Columbia - Gerontology Research Lab, Vancouver, British Columbia, Canada
A Study of LY900014 in Participants With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1392
- Registration Number
- NCT03214367
- Locations
- 🇺🇸
Valley Endocrine, Fresno, Fresno, California, United States
🇺🇸Physicians East, Greenville, North Carolina, United States
🇺🇸Diabetes and Endocrine Associates, La Mesa, California, United States
A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2020-03-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 933
- Registration Number
- NCT03214380
- Locations
- 🇺🇸
Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States
🇺🇸Aventiv Research, Columbus, Ohio, United States
🇺🇸Dallas Diabetes Endocrine Center, Dallas, Texas, United States
A Study of LY900014 in Elderly and Younger Adult Participants With Type 1 Diabetes Mellitus
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2020-04-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 80
- Registration Number
- NCT03166124
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss, Germany
Feasibility Trial Testing the Bionic Pancreas With ZP4207
- Conditions
- Interventions
- First Posted Date
- 2016-11-22
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 13
- Registration Number
- NCT02971228
- Locations
- 🇺🇸
MGH Diabetes Center, Boston, Massachusetts, United States
A Study of LY900014 Formulation in Healthy Participants
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT02942654
- Locations
- 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Singapore, Singapore
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.